Welcome to MatRx Therapeutics
Pioneering innovative hyaluronan-based therapies to treat the underlying cause of Chronic Obstructive Pulmonary Disease (COPD).
MatRx Therapeutics was founded in 2015 to commercialize therapies to treat the underlying cause of COPD
1
Early Research
MatRx founders have more than 20 years of foundational research at leading New York hospitals, supported by NIH grants and private foundations.
2
Animal Studies
Between 2005 and 2011, they conducted preclinical studies demonstrating positive impact of Hyaluronan in emphysema-induced mice.
3
Phase 1 Human Trials
Two human clinical trials were conducted in 2017 and 2021 further supporting that Hyaluronan is effective and safe as a COPD treatment.
4
Intellectual Property
MatRx has been granted treatment and biomarker patents for Hyaluronan and has patents filed in US and Europe.
5
Phase 2 Trial
MatRx is seeking $8 million in funding to conduct a Phase 2 clinical trial of up to 80 patients to further validate Hyaluronan's efficacy and safety.
MatRx Proprietary and Confidential
MatRx has a valuable patent portfolio
1
Compositions and Methods for Treating Elastic Fiber Breakdown*
This patent protects MatRx's therapeutic approach for treating COPD by targeting the underlying cause of lung tissue degradation.
2
Methods of Validating Candidate Compounds for use in treating COPD*
This patent, licensed from Columbia University, enables MatRx to identify and develop promising compounds for COPD treatment.
3
Hyaluroran Orphan Drug Status granted by FDA
The US Department of Health & Human Services has granted Hyaluronan Orphan Drug Status for the treatment of emphysema due to Alpha-1 antitrypsin deficiency.
*Patents available on demand
MatRx is expanding its patent portfolio
1
Composition for Treating Elastic Fiber Breakdown (US)
This patent protects MatRx's innovative approach to treating COPD by targeting the underlying cause of lung tissue degradation.
2
Methods and Composition for Treating Elastic Fiber Breakdown (Europe)
This patent expands MatRx's intellectual property protection, ensuring global coverage for its revolutionary COPD treatment.
MatRx Proprietary and Confidential
The MatRx Therapeutics Team
MatRx Therapeutics is led by an exceptional team of experienced researchers and clinicians who have dedicated their careers to unlocking new treatments for COPD. The founders, Dr. Gerard M. Turino and lead researcher Dr. Jerome O. Cantor, bring over 30 years of foundational research in lung disease and innovative approaches to addressing the underlying causes of COPD.
Dr. Gerard M. Turino, CEO and Founder
- Professor of Medicine at Mount Sinai Icahn School
- Senior Physician at Mount Sinai St. Luke's/Roosevelt Hospital
- John H. Keating Professor Emeritus at Columbia
- Founder of the James P. Mara Center for Lung Disease
- Former President of the American Thoracic Society
- Founding member of the Alpha-1 Foundation
- Co-founded the COPD Foundation, remains on Board
- Founded MatRx Therapeutics in 2015, CEO and Chairman
MatRx Proprietary & Confidential
Jerome O. Cantor, MD
- Distinguished medical professional and researcher
- Professor at St. John's University, expert in pulmonary pathophysiology
- Vice President, Ines Mandl Research Foundation
- Recipient of grants and awards for pulmonary pathophysiology research
- President of MatRx Therapeutics, led COPD treatment research
MatRx proprietary and confidential
MatRx is inviting you to become an investor in this groundbreaking therapy
MatRx Therapeutics has successfully completed animal and two Phase 1 human trials and is now seeking $8 million to advance its aerosolized hyaluronan (HA) therapy for COPD into a Phase 2 clinical trial to further validate the therapy in larger human sample size, targeted to begin in 2025.
$8M
Investment
To fund Phase 2 clinical trial
2025
Start
Projected start date
MatRx Proprietary & Confidential
COPD Market Size
$11.5B
Market Size
2023
$30.8B
Projected
2033
The COPD global market is projected to grow significantly. New drug approvals drive growth, including Sanofi/Regeneron’s Dupixent. Additional pipeline agents are expected to be approved during the forecast period, further expanding the market.
MatRx proprietary and confidential
Competitive differentiation of Hyaluronan therapy
•The only treatment that addresses the underlying cause of COPD
•Easy to administer – aerosolized treatment without clinical difficulty
•Inexpensive to manufacture
•Anti-inflammatory and safe
•Can be combined with other aerosolized treatments such as bronchodilators
•Studies have shown beneficial results in as little as 2 weeks
Aerosolized Hyaluronan can be utilized as an adjunctive therapy in conjunction with current COPD pharmacotherapies, potentially providing a comprehensive approach to both short-term symptom management and long-term prevention of disease progression.
MatRx proprietary and confidential
Thank You
Thank you for your time and consideration. We appreciate your interest in MatRx Therapeutics and our innovative approach to COPD treatment. MatRx is excited to move forward with our Phase 2 clinical trial and believes our therapy has the potential to significantly impact the lives of COPD patients.
This is an exceptional opportunity for investors to be part of a groundbreaking advancement in COPD care, and we would be thrilled to have you onboard.
We welcome any questions or feedback you may have.
Contact: James Turino james@tkanyc.com